Glucos Fresenius Kabi

Glucos Fresenius Kabi is an intravenous solution for injection that contains glucose as the sole active ingredient. It is supplied in a sterile solution form, marketed in the European Union, and classified as an excipient used to provide energy and maintain blood glucose levels during intravenous therapy. The product is prescription‑only and is commonly employed in clinical settings for fluid replacement, parenteral nutrition, and treatment of hypoglycemia.

Glucos Fresenius Kabi is indicated for several clinical situations where rapid glucose delivery and fluid support are required.

- Treatment of acute hypoglycemia in hospitalized patients. - Component of parenteral nutrition regimens for patients unable to eat orally. - Fluid replacement in patients with dehydration or electrolyte imbalance. - Support during surgical procedures requiring intravenous glucose. - Adjunct therapy for patients receiving medications that may lower blood glucose levels.

Glucos Fresenius Kabi may be associated with a range of adverse reactions, most of which are related to the intravenous administration of glucose.

Common: - Mild hyperglycemia or transient rise in blood glucose. - Local irritation or pain at the infusion site. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness during rapid infusion. - Electrolyte shifts, particularly potassium changes.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypersensitivity reactions, including rash or urticaria. - Fluid overload causing pulmonary edema. - Hyperosmolar hyperglycemic state in susceptible patients. - Metabolic acidosis secondary to rapid glucose metabolism.

When using Glucos Fresenius Kabi, clinicians should consider several safety factors to minimize risk.

- Assess baseline blood glucose and monitor levels frequently during infusion. - Adjust infusion rate in patients with renal or cardiac insufficiency to avoid fluid overload. - Use caution in patients with known hypersensitivity to glucose solutions or excipients. - Verify compatibility with other intravenous medications before co‑administration. - Consider electrolyte status, especially potassium and sodium, before and during therapy. - Document and report any unexpected adverse reactions promptly.

Glucos Fresenius Kabi can interact with other agents administered intravenously or affect metabolic pathways.

Avoid: - Concurrent infusion of high‑dose insulin without appropriate glucose monitoring. - Mixing with calcium‑containing solutions that may precipitate. - Co‑administration with medications that significantly lower blood glucose (e.g., sulfonylureas) without dose adjustment.

Use with caution: - Concurrent use of diuretics that may alter fluid balance. - Administration alongside beta‑blockers, which can mask hypoglycemia symptoms. - Co‑infusion with potassium chloride solutions; monitor serum potassium. - Use in patients receiving total parenteral nutrition containing other carbohydrate sources. - Combination with vasopressors; monitor hemodynamic response.